Resources

Resource centre

Article

PharmTech - Unlocking Formulation Expertise

As the industry enters a phase where the patents of many major drugs will expire and the use of more novel therapeutic modalities is increasing, the desire to partner up with a company that can offer significant expertise is also rising. A new article featuring Quotient Sciences' Vanessa Zann, Senior Drug Development Consultant and Chris Roe, Principal Research Fellow.

Moving Drug Substance Off the Critical Path — Streamlined Strategies to Accelerate to First-in-Human & Beyond

Join Quotient’s Director of Drug Development Consulting, Dr Stephen McQuaker Vice President of Bioanalysis, Dr Stuart McDougall, as he explores case studies to demonstrate how drug substance and drug product development plans can be accelerated through innovative science and expertise to get drug substance off the critical path.

Overcoming Complex Formulation Challenges: Integrated Strategies for Poor Solubility, Modified Release & Pediatrics

Join Quotient’s Executive Director of Drug Development Consulting, John McDermott, as he discusses how an integrated program design can simplify development processes for complex molecules and reduce overall costs.

Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial

Synucleinopathies such as Parkinsońs disease (PD), Dementia with Lewy odies (DLB) and Multiple System Atrophy (MSA) are characterized by deposition of misfolded and aggregated a-synuclein. Small aggregates (oligomers) of a-synuclein have been shown to be the most relevant neurotoxic species and are targeted by anle138b, an orally bioavailable small molecule compound which shows strong disease-modifying effects in animal models of synucleinopathies.

Scientific Posters

A First-in-Human (FIH) Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses, and Alternative Formulations of R941552 (R552): A selective Receptor Interacting Protein 1 (RIP1) Kinase Inhibitor

Quotient Sciences Poster: A First-in-Human (FIH) Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses, and Alternative Formulations of R941552 (R552): A selective Receptor Interacting Protein 1 (RIP1) Kinase Inhibitor

A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors

Quotient Sciences and Kadmon co-authored scientific publications for their recent NDA approved drug Belumosudil.

Phase 1 Studies to Evaluate the Food Effect and Relative Bioavailability of Tablet and Capsule Formulations of Belumosudil in Healthy Adult Subjects

Quotient Sciences and Kadmon co-authored scientific publications on their recent NDA approved drug Belumosudil.

Absolute Bioavailability, Mass Balance, and Metabolic Profiling Assessment of [14C]-Belumosudil in Healthy Men: A Phase 1, Open-Label, 2-Part Study

Quotient Sciences and Kadmon co-authored scientific publications on their recent NDA approved drug Belumosudil.

ACCP: A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors

Quotient Sciences, Kadmon and Nuventra, Co-Authored Scientific Publication assessing Belumosudil, a selective Rho-associated protein kinase 2 inhibitor. Inhibition of Rho-associated protein kinase 2 has emerged as a promising treatment for chronic graft-versus-host disease by restoring immune homeostasis and reducing fibrosis.

Quotient Sciences_Astrazeneca_Scientific Publication- Characterization of Clinical ADME & Pharmacokinetics of Velsecorat Using an IV Microtracer Combined with an Inhaled Dose in Healthy Subjects

Quotient Sciences and Astrazeneca Co-Authored Scientific Publication evaluating the use of intravenous 14C dosing in healthy volunteer subjects to understand the metabolism for an inhaled drug product.

Development of a Once‑Daily Modified‑Release Formulation for the Short Half‑Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology

Quotient Sciences Scientific Publication- Development of a Once‑Daily Modified‑Release Formulation for the Short Half‑Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology

Human ADME Capabilities

With over 30 years’ experience as a world leading provider of human ADME 14C radiolabeled studies, we have the scientific expertise and operational know-how to design and deliver human ADME programs in preparation for NDA, MAA and global regulatory filings.

Scientific Posters

An integrated radiolabelled study to determine the mass balance, metabolite profile and identification, and absolute bioavailability of nolasiban in healthy female subjects

Quotient Sciences Poster : An Integrated Radiolabelled Study to Determine the Mass Balance, Metabolite Profile and Identification and Absolute Bioavailability of Nolasiban in Healthy Female Subjects

Formulation Development Drug Substance Clinical Trial Manufacturing Commercial Manufacturing Bioanalysis Clinical Pharmacology Data Sciences Drug Development Consulting

Ask us a question